<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37597847</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003270</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-003270</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterised by unpredictable flares. Many patients with SLE are unable to achieve the recommended treatment goal of remission or the intermediate, yet still clinically beneficial, goal of Lupus Low Disease Activity State (LLDAS) with standard of care (SoC) treatments. LLDAS is an emerging treat-to-target goal in SLE with the aim of reducing organ damage and mortality. A high unmet need remains in SLE and mainstay glucocorticoid treatment is associated with unacceptable toxicity. The recently approved type I interferon receptor antagonist anifrolumab is a new treatment option for this historically underserved patient population. In phase 3 trials, a higher percentage of patients on anifrolumab achieved remission, as defined by the Definition Of Remission In SLE (DORIS), and LLDAS compared with placebo. Real-world clinical experience with anifrolumab use is still limited. Until real-world study results and updated treatment guidelines are available, personal expert clinical experience supported by data may inform clinical decision-making. This viewpoint article discusses four example patient types that could be considered for anifrolumab treatment based on (1) high-risk features early in the disease course, (2) inability to achieve and (3) maintain at least LLDAS, or (4) a desire to reduce or stop SoC. These patients with high unmet need may benefit from the addition of anifrolumab to SoC to achieve or maintain the therapeutic goals of LLDAS or DORIS remission.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yoshiya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0807-7139</Identifier><AffiliationInfo><Affiliation>The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan tanaka@med.uoeh-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>38RL9AE51Q</RegistryNumber><NameOfSubstance UI="C582345">anifrolumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="N">Clinical Decision-Making</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Biological Therapy</Keyword><Keyword MajorTopicYN="N">Glucocorticoids</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword></KeywordList><CoiStatement>Competing interests: YT has received grant/research support from Chugai, Eisai, Mitsubishi-Tanabe and Taisho; received speaking fees and/or honoraria from AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Pfizer, Taiho and Taisho.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>19</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37597847</ArticleId><ArticleId IdType="pmc">PMC10441065</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003270</ArticleId><ArticleId IdType="pii">rmdopen-2023-003270</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Piga M, Arnaud L. The main challenges in systemic lupus erythematosus: where do we stand? J Clin Med 2021;10:243. 10.3390/jcm10020243</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10020243</ArticleId><ArticleId IdType="pmc">PMC7827672</ArticleId><ArticleId IdType="pubmed">33440874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus Foundation of America . Lupus facts and statistics. 2016. Available: https://www.lupus.org/resources/lupus-facts-and-statistics [Accessed 5 Apr 2023].</Citation></Reference><Reference><Citation>Kaul A, Gordon C, Crow MK, et al. . Systemic lupus erythematosus. Nat Rev Dis Primers 2016;2:16039. 10.1038/nrdp.2016.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SA, Allen E, Rahman A, et al. . Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009;48:673&#x2013;5. 10.1093/rheumatology/kep062</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep062</ArticleId><ArticleId IdType="pubmed">19359343</ArticleId></ArticleIdList></Reference><Reference><Citation>Segura BT, Bernstein BS, McDonnell T, et al. . Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology (Oxford) 2020;59:524&#x2013;33. 10.1093/rheumatology/kez292</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez292</ArticleId><ArticleId IdType="pmc">PMC8414923</ArticleId><ArticleId IdType="pubmed">31377781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al. . 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736&#x2013;45. 10.1136/annrheumdis-2019-215089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte A, Danza A, Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol 2018;30:482&#x2013;9. 10.1097/BOR.0000000000000527</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000527</ArticleId><ArticleId IdType="pubmed">29870497</ArticleId></ArticleIdList></Reference><Reference><Citation>Luijten R, Fritsch-Stork RD, Bijlsma JWJ, et al. . The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev 2013;12:617&#x2013;28. 10.1016/j.autrev.2012.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2012.12.001</ArticleId><ArticleId IdType="pubmed">23232124</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford) 2020;59:v29&#x2013;38. 10.1093/rheumatology/keaa382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa382</ArticleId><ArticleId IdType="pmc">PMC7719040</ArticleId><ArticleId IdType="pubmed">33280012</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca . Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus. 2021. Available: https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle.html [Accessed 5 Apr 2023].</Citation></Reference><Reference><Citation>AstraZeneca . Saphnelo approved in Japan for systemic lupus erythematosus. 2021. Available: https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-japan-for-sle.html [Accessed 5 Apr 2023].</Citation></Reference><Reference><Citation>AstraZeneca . Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus. 2022. Available: https://www.astrazeneca.com/media-centre/press-releases/2022/saphnelo-approved-in-eu-for-sle.html [Accessed 5 Apr 2023].</Citation></Reference><Reference><Citation>AstraZeneca Canada Inc . SAPHNELO anifrolumab for injection. Product monograph. 2021. Available: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/saphnelo-product-monograph-en.pdf [Accessed 5 Apr 2023].</Citation></Reference><Reference><Citation>AstraZeneca Pharmaceuticals LP . SAPHNELO (anifrolumab-fnia) injection, for intravenous use. US prescribing information. 2021. Available: http://www.azpicentral.com/pi.html?product=saphnelo [Accessed 5 Apr 2023].</Citation></Reference><Reference><Citation>AstraZeneca Pty Ltd MPN . SAPHNELO&#xae; (anifrolumab) concentrated solution for infusion. Australian product information. 2022. Available: https://www.guildlink.com.au/gc/ws/astra/pi.cfm?product=appsaphn10322 [Accessed 5 Apr 2023].</Citation></Reference><Reference><Citation>van Vollenhoven RF, Bertsias G, Doria A, et al. . 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 2021;8:e000538. 10.1136/lupus-2021-000538</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId><ArticleId IdType="pmc">PMC8614136</ArticleId><ArticleId IdType="pubmed">34819388</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, et al. . Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016;75:1615&#x2013;21. 10.1136/annrheumdis-2015-207726</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandane-Rathnayake R, Golder V, Louthrenoo W, et al. . Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. Lancet Rheumatol 2022;4:e822&#x2013;30. 10.1016/S2665-9913(22)00304-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00304-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Hoi AY-B, et al. . Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther 2017;19:62. 10.1186/s13075-017-1256-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1256-6</ArticleId><ArticleId IdType="pmc">PMC5359963</ArticleId><ArticleId IdType="pubmed">28320433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandane-Rathnayake R, Louthrenoo W, Hoi A, et al. . 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus&#x2014;a multinational observational cohort study. Arthritis Res Ther 2022;24:70. 10.1186/s13075-022-02756-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02756-3</ArticleId><ArticleId IdType="pmc">PMC8919535</ArticleId><ArticleId IdType="pubmed">35287720</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK. Advances in understanding the role of type I Interferons in systemic lupus erythematosus. Curr Opin Rheumatol 2014;26:467&#x2013;74. 10.1097/BOR.0000000000000087</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000087</ArticleId><ArticleId IdType="pmc">PMC4280994</ArticleId><ArticleId IdType="pubmed">25010440</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, et al. . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211&#x2013;21. 10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Morand EF, Bruce IN, et al. . Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 2019;1:e208&#x2013;19. 10.1016/S2665-9913(19)30076-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376&#x2013;86. 10.1002/art.39962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian KC, Furie R, Morand EF, et al. . A randomized, placebo&#x2010;controlled phase III extension trial of the long&#x2010;term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol 2023;75:253&#x2013;65. 10.1002/art.42392</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42392</ArticleId><ArticleId IdType="pmc">PMC10098934</ArticleId><ArticleId IdType="pubmed">36369793</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Van Vollenhoven R, Furie R, et al. . Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab. Ann Rheum Dis 2023;82(Suppl 1):33&#x2013;4. 10.1136/annrheumdis-2023-eular.1568</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2023-eular.1568</ArticleId><ArticleId IdType="pmc">PMC10176410</ArticleId><ArticleId IdType="pubmed">36690388</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Ugarte-Gil MF, Alarc&#xf3;n GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol 2017;13:799&#x2013;814. 10.1080/1744666X.2017.1327352</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2017.1327352</ArticleId><ArticleId IdType="pubmed">28471259</ArticleId></ArticleIdList></Reference><Reference><Citation>Langham J, Barut V, Samnaliev M, et al. . Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis. Rheumatol Adv Pract 2021;5:rkab061. 10.1093/rap/rkab061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkab061</ArticleId><ArticleId IdType="pmc">PMC8452998</ArticleId><ArticleId IdType="pubmed">34557623</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, et al. . Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis 2020;76:265&#x2013;81. 10.1053/j.ajkd.2019.10.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA. Benlysta (belimumab) . An overview of Benlysta and why it is authorised in the EU. 2021. Available: www.ema.europa.eu/en/documents/overview/benlysta-epar-medicine-overview_en.pdf [Accessed 5 Jun 2023].</Citation></Reference><Reference><Citation>FDA . Benlysta, prescribing information. 2011. Available: www.accessdata.fda.gov/drugsatfda_docs/label/2020/125370s073,761043s013lbl.pdf [Accessed 5 Jun 2023].</Citation></Reference><Reference><Citation>Jayne D, Rovin B, Mysler EF, et al. . Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022;81:496&#x2013;506. 10.1136/annrheumdis-2021-221478</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId><ArticleId IdType="pmc">PMC8921596</ArticleId><ArticleId IdType="pubmed">35144924</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca . Identifier NCT05138133, phase 3 study of anifrolumab in adult patients with active proliferative lupus nephritis (IRIS). Available: https://clinicaltrials.gov/study/NCT05138133?cond=Lupus%20Nephritis&amp;term=phase%203&amp;intr=Anifrolumab&amp;rank=1 [Accessed 6 Jun 2023].</Citation></Reference><Reference><Citation>Vital EM, Merrill JT, Morand EF, et al. . Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 2022;81:951&#x2013;61. 10.1136/annrheumdis-2021-221425</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221425</ArticleId><ArticleId IdType="pmc">PMC9213795</ArticleId><ArticleId IdType="pubmed">35338035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, Van Vollenhoven R, Tanaka Y, et al. . Efficacy of anifrolumab in serological subgroups of patients with SLE participating in 2 phase 3 trials [abstract]. Arthritis Rheumatol
2021;73. Available: https://acrabstracts.org/abstract/efficacy-of-anifrolumab-in-serological-subgroups-of-patients-with-sle-participating-in-2-phase-3-trials/</Citation></Reference><Reference><Citation>Kalunian K, Dall&#x2019;Era M, Furie R, et al. . Anifrolumab results in favorable responses regardless of SLE disease duration: post hoc analysis of data from 2 phase 3 trials [abstract]. Arthritis Rheumatol
2021;73. Available: https://acrabstracts.org/abstract/anifrolumab-results-in-favorable-responses-regardless-of-sle-disease-duration-post-hoc-analysis-of-data-from-2-phase-3-trials</Citation></Reference><Reference><Citation>Bruce IN, van Vollenhoven RF, Morand EF, et al. . Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post-hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford) 2023;62:1526&#x2013;34. 10.1093/rheumatology/keac491</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac491</ArticleId><ArticleId IdType="pmc">PMC10070065</ArticleId><ArticleId IdType="pubmed">36018235</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Abreu G, Furie RA, et al. . Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis 2023;82:639&#x2013;45. 10.1136/ard-2022-222748</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222748</ArticleId><ArticleId IdType="pmc">PMC10176410</ArticleId><ArticleId IdType="pubmed">36690388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi J, Hanaoka H, Saito S, et al. . Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. Rheumatology (Oxford) 2022;61:3777&#x2013;91. 10.1093/rheumatology/keac002</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac002</ArticleId><ArticleId IdType="pubmed">35015824</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Trasieva T, Berglind A, et al. . Lupus low disease activity state (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the phase IIb MUSE trial of anifrolumab. Ann Rheum Dis 2019;78:706&#x2013;13. 10.1136/annrheumdis-2018-214487</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214487</ArticleId><ArticleId IdType="pmc">PMC5909750</ArticleId><ArticleId IdType="pubmed">29420200</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E, Abreu G, Furie R, et al. . Attainment of the lupus low disease activity state in response to anifrolumab in 2 phase 3 trials [abstract]. Arthritis Rheumatol
2021;73. Available: https://acrabstracts.org/abstract/attainment-of-the-lupus-low-disease-activity-state-in-response-to-anifrolumab-in-2-phase-3-trials</Citation></Reference><Reference><Citation>Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol 2017;28:4&#x2013;12. 10.31138/mjr.28.1.4</Citation><ArticleIdList><ArticleId IdType="doi">10.31138/mjr.28.1.4</ArticleId><ArticleId IdType="pmc">PMC7045928</ArticleId><ArticleId IdType="pubmed">32185248</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Morand EF, Askanase AD, et al. . Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 2021;30:1254&#x2013;63. 10.1177/09612033211014267</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211014267</ArticleId><ArticleId IdType="pubmed">33977796</ArticleId></ArticleIdList></Reference><Reference><Citation>Flouda S, Sampatakaki E, Moysidou GS, et al. . Anifrolumab for refractory skin disease in systemic lupus erythematosus (SLE): a single center case series. Ann Rheum Dis 2023;82(Suppl 1):1468. 10.1136/annrheumdis-2023-eular.6077</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2023-eular.6077</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MA, Khan FH, Khan HB, et al. . Role of anifrolumab in refractory cutaneous manifestations of lupus erythematosus: a case series and literature review. Cureus 2023;15:e39553. 10.7759/cureus.39553</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.39553</ArticleId><ArticleId IdType="pmc">PMC10292022</ArticleId><ArticleId IdType="pubmed">37378095</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xfc;&#xdf; M, Piantoni S, Wincup C, et al. . Rapid response of refractory systemic lupus erythematosus skin manifestations to anifrolumab&#x2014;a case-based review of clinical trial data suggesting a domain-based therapeutic approach. J Clin Med 2022;11:3449. 10.3390/jcm11123449</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11123449</ArticleId><ArticleId IdType="pmc">PMC9225134</ArticleId><ArticleId IdType="pubmed">35743519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian KC, Furie R, Morand EF, et al. . A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol 2023;75:253&#x2013;65. 10.1002/art.42392</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42392</ArticleId><ArticleId IdType="pmc">PMC10098934</ArticleId><ArticleId IdType="pubmed">36369793</ArticleId></ArticleIdList></Reference><Reference><Citation>Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. . Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381&#x2013;90. 10.1002/art.21405</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21405</ArticleId><ArticleId IdType="pubmed">16258899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M, Saccon F, Zen M, et al. . Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting. Arthritis Rheumatol 2020;72:1314&#x2013;24. 10.1002/art.41253</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41253</ArticleId><ArticleId IdType="pubmed">32275125</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerosa M, Beretta L, Ramirez GA, et al. . Long-term clinical outcome in systemic lupus erythematosus patients followed for more than 20 years: the Milan systemic lupus erythematosus consortium (SMiLE) cohort. J Clin Med 2022;11:3587. 10.3390/jcm11133587</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11133587</ArticleId><ArticleId IdType="pmc">PMC9267338</ArticleId><ArticleId IdType="pubmed">35806873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020;59:v69&#x2013;81. 10.1093/rheumatology/keaa403</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa403</ArticleId><ArticleId IdType="pmc">PMC7719039</ArticleId><ArticleId IdType="pubmed">33280011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, van Vollenhoven RF, Psachoulia K, et al. . Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. Lupus Sci Med 2023;10:e000761. 10.1136/lupus-2022-000761</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000761</ArticleId><ArticleId IdType="pmc">PMC9843193</ArticleId><ArticleId IdType="pubmed">36639192</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>